APA (7th ed.) Citation

Zhao, B., Yao, L., & Ma, W. (2024). Osimertinib versus Durvalumab versus observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of thoracic oncology, 19(5), . https://doi.org/10.1016/j.jtho.2024.01.020

Chicago Style (17th ed.) Citation

Zhao, Binghao, Longping Yao, and Wenbin Ma. "Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-mutant NSCLC." Journal of Thoracic Oncology 19, no. 5 (2024). https://doi.org/10.1016/j.jtho.2024.01.020.

MLA (9th ed.) Citation

Zhao, Binghao, et al. "Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-mutant NSCLC." Journal of Thoracic Oncology, vol. 19, no. 5, 2024, https://doi.org/10.1016/j.jtho.2024.01.020.